Bladder cancer is the 6th most common type of cancer in the US1

~80,000

~60,000

New cases of bladder cancer in 2020

New cases of NMIBC1

~80,000

New cases of bladder cancer in 2020

~60,000

New cases of NMIBC1
The rates of recurrence and progression to muscle-invasive bladder cancer (MIBC) are important surrogate endpoints for overall prognosis, as these are major determinants of long-term outcome. Therefore, the ability to predict risk of recurrence and progression and treat the disease appropriately is important. The AUA/SUO guideline provides a risk-stratified clinical framework for the management of NMIBC.

AUA risk stratification for non-muscle invasive bladder cancer 

LOW-RISK

LGa solitary Ta ≤ 3cm

PUNLMPb

INTERMEDIATE-RISK

Recurrence within 1 year, LG Ta

Solitary LG Ta > 3cm

LG Ta, multifocal

HGc Ta, ≤ 3cm

LG T1

HIGH-RISK

HG T1
Any recurrent, HG Ta
HG Ta, > 3cm (or multifocal)
Any CISd
Any BCG failure in HG patient
Any variant histology
Any LVIe
Any HG prostatic urethral involvement

aLG = low grade; bPUNLMP = papillary urothelial neoplasm of low malignant potential; cHG = high grade; dCIS = carcinoma in situ; eLVI = lymphovascular invasion

After TURBT, patients are staged, graded, and risk is classified2,3

UP TO 43%

of new NMIBC cases will be classified as high-risk4,5*

A large proportion of high-risk patients will experience recurrence following intravesical therapy6

Up to

of high-risk patients will recur within 1 year

Up to

of high-risk patients will recur within 5 years

IT’S TIME FOR MORE OPTIONS
IN HIGH-RISK NMIBC >

IT’S TIME FOR MORE OPTIONS
IN HIGH-RISK NMIBC >

References: 1. SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed October 21, 2020. 2. American Urological Association. (2020). Diagnosis and Treatment of Non Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020). https://www.auanet.org//guidelines/bladder-cancer-non-muscle-invasive-guideline. 3. Anastasiadis A, De Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4(1):13-32. 4. Danforth KN, Sidell MA, Luong TQ, et al.Care quality and variability in the use of intravesical therapy for initial treatment of non-muscle invasive bladder cancer within a large, diverse integrated delivery system. Urology. 2019. https://doi.org/10.1016/j.urology.2019.03.035. [Epub ahead of print.] 5. Williams S, Luong T, Yi D, et al. Initial treatment of non-muscle invasive bladder cancer (NMIBC) in a large integrated delivery system. J Urol. 2018;199(4s):e948. 6. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27(34): 5680-5684.

Copyright FerGene, Inc. 2020/11 US-URONC-2000010